Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
ViewAttendees 6

QSP SIG Event: Strategies for Successful Application of QSP Platform Models for Clinical Development and Regulatory Engagement

Panel Discussion

Monday, November 11, 2024
6:00 PM – 6:30 PM MST
Location: Sonoran Sky Ballroom 5 - 8

    Panelist(s)

  • RA

    Richard Allen, PhD

    Research Fellow and Quantitative Systems Pharmacology Lead
    Pfizer, United States

    Disclosure(s): Pfizer Inc: Employment (Ongoing)

  • BS

    Brian Schmidt

    Disclosure information not submitted.

  • Jin Jin, PhD (she/her/hers)

    Executive Director and Senior Fellow
    Genentech, Inc.
    Foster City, California, United States

    Disclosure(s): Genentech, Inc.: Employment (Ongoing)

  • Lourdes Cucurull-Sanchez, PhD MPhil (she/her/hers)

    Platform Scientific Lead
    Pharmetheus

    Disclosure(s): GSK: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

  • Susana Zaph, PhD (she/her/hers)

    Senior Director & Head of Translational Disease Modeling - US
    Sanofi
    Bridgewater, New York, United States

    Disclosure(s): Sanofi: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Disclosure(s):
Richard Allen, PhD: Pfizer Inc: Employment (Ongoing)
Jin Jin, PhD: Genentech, Inc.: Employment (Ongoing)
Lourdes Cucurull-Sanchez, PhD MPhil: GSK: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Susana Zaph, PhD: Sanofi: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)